ClinicalTrials.govpublic full text
A Trial Evaluating Stereotactic Radiotherapy Plus Durvalumab Continuation for Patients With NSCLC Metachronous Oligometastatic Disease Under Durvalumab Consolidation Following Chemoradiation
nsclc, anti-pd-l1, durvalumab, stereotactic radiation therapy, oligometastatic disease, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 880671
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.